Large addressable Potential to treat around 200,000 patients with advanced heart failure annually, with initial focus on the 50,000 most severe patients. This creates a sizable market opportunity for hospital systems, insurers, and procurement channels targeting high-acuity cardiac care.

unmet need FLOWMAKER offers intraventricular, wireless flow acceleration with minimal invasiveness and no external driveline, implanted via a 90-minute beating-heart procedure. This differentiates from traditional surgeries and may drive adoption among centers seeking reduced risk and quicker recovery for severe heart failure cases.

Strategic partnerships Diverse investor and regional support including EU funding, Bpifrance, and regional bodies, plus collaborations with prominent cardiac surgeons and researchers. This landscape can facilitate co-development opportunities, joint ventures, and accelerated access in European markets.

Global demand fit A compact, wireless, and adjustable therapy that functions similarly to a pacemaker in terms configurability positions FLOWMAKER to align with growing demand for personalized, minimally invasive cardiac therapies across hospital networks and specialized centers.

Funding runway Current funding of $147M combined with a revenue run rate under $1M suggests significant capacity for sales expansion and installation scale post-clinical validation. This signals readiness for enterprise sales to large cardiology departments and hospital systems seeking innovative devices.